Suzuki K, Takanashi K, Naide Y, Fujita T, Ogawa T, Hirabayashi S, Tamai H, Yanaoka M, Ishiguro K, Asano H
Hinyokika Kiyo. 1986 Sep;32(9):1387-408.
MK-0787 (Imipenem)/MK-0791 (Cilastatin sodium), a new compound of Thienamycin, was administered in treatment of 35 patients (36 cases) with chronic complicated UTI or for prevention of serious infections with much complicated factors. The patients were principally treated at a daily dose of 1 g for over 10 days. The efficacy rate of 26 patients who were evaluable in the early phase (4-7 days) was 88.5%, while it became up to 92.3% in the final phase judgment. As for clinical usefulness, the result was obtained to be as high as that of the clinical efficacy. In bacteriological study, 35 strains were clinically isolated including 7 strains of P. aeruginosa from UTI. All the strains disappeared with an eradication rate of 100% after treatment. Strains appearing after Imipenem/Cilastatin sodium treatment mainly consisted of fungi. Usefulness judgements tended to be greater in the final phase than in the early phase. As for side effects, vomiting was recorded in one case, in which the administration was discontinued. In laboratory findings there were 3 cases with elevated GPT, 2 cases with elevated GOT, one case with elevated gamma-GTP, one with thrombocytopenia, and one with eosinophilia each, but these abnormal values were slight and transient. In summary our clinical study showed that Imipenem/Cilastatin sodium was a very effective antibiotic in treatment on moderate or serious UTI or preventive use for infections in compromised hosts. Considering the features of this agent, it might be more effective and useful for clinical use in treatment on polymicrobial infections including stubborn organisms than any other antimicrobial compounds. Furthermore, it was safe and well tolerable in a long term treatment.
亚胺培南/西司他丁钠（MK-0787/ MK-0791），一种新型硫霉素化合物，用于治疗35例（36例次）慢性复杂性尿路感染患者或预防伴有多种复杂因素的严重感染。患者主要接受每日1克的剂量治疗，疗程超过10天。在早期阶段（4 - 7天）可评估的26例患者中，有效率为88.5%，而在最终阶段判定时有效率高达92.3%。至于临床实用性，结果显示与临床疗效一样高。在细菌学研究中，临床分离出35株菌株，其中7株来自尿路感染的铜绿假单胞菌。治疗后所有菌株均消失，根除率达100%。亚胺培南/西司他丁钠治疗后出现的菌株主要为真菌。实用性判定在最终阶段往往比早期阶段更高。至于副作用，有1例记录到呕吐，因此停药。实验室检查结果显示，有3例谷丙转氨酶升高，2例谷草转氨酶升高，1例γ-谷氨酰转肽酶升高，各有1例血小板减少和嗜酸性粒细胞增多，但这些异常值轻微且短暂。总之，我们的临床研究表明，亚胺培南/西司他丁钠是治疗中度或重度尿路感染或预防免疫功能低下宿主感染的非常有效的抗生素。考虑到该药物的特性，在治疗包括顽固微生物在内的多种微生物感染方面，它可能比任何其他抗菌化合物更有效且更具临床实用性。此外，在长期治疗中它是安全且耐受性良好的。
